gatehousebio

@pobronson @alexlorestani @SOSV @ajalabs_co @DiademBio @IntrinsicMed Couldn’t agree with @alexlorestani more! @pobronson , it’s always a pleasure!

@alexlorestani @SOSV In a world that idolizes “balance,” it can seem absurd that @alexlorestani wasn’t the only founder I was working with this weekend. @ajalabs_co @DiademBio @IntrinsicMed @gatehousebio But when work is fun, and I love our founders, it makes me happy.

Our ability to identify small RNA mutations opens a novel class of targetable biology and an opportunity for a portfolio of oligonucleotide therapeutics that target specific groups of patients businesswire.com/news/home/2022…

"Together, we are steadily closing the gap between RNA modality, AI, and disease biology with the shared goal of discovering and developing novel treatments in heart failure." businesswire.com/news/home/2022…

Over the last 3 years we’ve been characterizing small RNA mutations and developing knowledge graphs to model their role in disease. The collaboration with AstraZeneca moves us closer towards realizing our vision of bringing therapeutics from discovery... businesswire.com/news/home/2022…